The Journal of Immunology, Vol 141, Issue 1 131-138, Copyright © 1988 by American Association of Immunologists

ARTICLES

Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses

DA Hafler, J Ritz, SF Schlossman and HL Weiner
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.

The immunologic responses to anti-T4 and anti-T11 mAb infusions were assessed in subjects with chronic progressive multiple sclerosis as part of phase I clinical studies. Eight subjects received five daily infusions (0.2 mg/kg/day) of either anti-T11 (CD2) or anti-T4 (CD4) murine mAb. It was found that in vivo anti-T cell mAb infusions specifically suppress in vitro measurements of the human immune response; anti-T11 mAb blocked T cell activation via the CD2 SRBC- binding protein, and anti-T4 mAb infusions abolished PWM-induced Ig synthesis without lysis of the CD4+ T cell subpopulations. With repeated infusions of the anti-T11 mAb in three subjects, anti-mouse antibodies were found in the circulation. Although the majority of human anti-mouse antibody was not isotype specific, significant anti- idiotypic-like activity was observed after repeated infusions in two of three subjects. The human anti-mouse antibodies were almost exclusively of the IgG isotype. The magnitude of the human anti-mouse response was significantly less after administration of either anti-T11 or anti-T4 as compared with anti-T12 mAb. Murine anti-T cell mAb can provide a specific, benign form of acute immunosuppression in humans. However, repeated administration of these reagents in more chronic diseases can result in anti-Id-like antibodies that block binding of the anti-T cell mAb to the T cell surface.

This article has been cited by other articles:

				S. Nakane, H. Matsuo, H. Goto, M. Yoshinaga-Matsumoto, I. Ohtsuru, K. Ichinose, H. Onodera, M. Yoshida, and N. Shibuya Cytapheresis with a filter for selective removal of CD4+ T cells in experimental autoimmune encephalomyelitis Multiple Sclerosis, December 1, 2003; 9(6): 579 - 584. [Abstract] [PDF]

				M. P. Reddy, C. A. S. Kinney, M. A. Chaikin, A. Payne, J. Fishman-Lobell, P. Tsui, P. R. Dal Monte, M. L. Doyle, M. R. Brigham-Burke, D. Anderson, et al. Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4 J. Immunol., February 15, 2000; 164(4): 1925 - 1933. [Abstract] [Full Text] [PDF]

				U. Koch, S. Choksi, L. Marcucci, and R. Korngold A Synthetic CD4-CDR3 Peptide Analog Enhances Skin Allograft Survival Across a MHC Class II Barrier J. Immunol., July 1, 1998; 161(1): 421 - 429. [Abstract] [Full Text] [PDF]

				T. Satoh, J. M. Aramini, S. Li, T. M. Friedman, J. Gao, A. E. Edling, R. Townsend, U. Koch, S. Choksi, M. W. Germann, et al. Bioactive Peptide Design Based on Protein Surface Epitopes. A CYCLIC HEPTAPEPTIDE MIMICS CD4 DOMAIN 1 CCprime LOOP AND INHIBITS CD4 BIOLOGICAL FUNCTION J. Biol. Chem., May 2, 1997; 272(18): 12175 - 12180. [Abstract] [Full Text] [PDF]

				U. Koch and R. Korngold A Synthetic CD4-CDR3 Peptide Analog Enhances Bone Marrow Engraftment Across Major Histocompatibility Barriers Blood, April 15, 1997; 89(8): 2880 - 2890. [Abstract] [Full Text] [PDF]

				S. Li, J. Gao, T. Satoh, T. M. Friedman, A. E. Edling, U. Koch, S. Choksi, X. Han, R. Korngold, and Z. Huang A computer screening approach to immunoglobulin superfamily structures and interactions: Discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics PNAS, January 7, 1997; 94(1): 73 - 78. [Abstract] [Full Text] [PDF]